Lyon, France, January 20, 2026 — MaaT Pharma, a late-stage clinical biotechnology company developing microbiome-driven immunotherapies, announced that the first patient has been randomized in the IMMUNOLIFE Phase 2 clinical trial. The study, sponsored by Gustave Roussy, is evaluating MaaT033, an oral pooled fecal microbiotherapy, in combination with cemiplimab, a PD-1 inhibitor, to improve outcomes in patients with advanced non-small cell lung cancer (NSCLC) who have developed resistance to immune checkpoint inhibitors following antibiotic-induced gut dysbiosis.
Science Significance
Scientifically, the IMMUNOLIFE study addresses a growing body of evidence linking gut microbiome composition to immunotherapy response. Antibiotic exposure is increasingly recognized as a driver of immune checkpoint inhibitor (ICI) resistance, particularly in NSCLC. MaaT033 is designed to restore microbiome diversity and immune homeostasis by delivering a high-richness, donor-derived microbial ecosystem enriched with anti-inflammatory species. By modulating gut-immune crosstalk, the therapy aims to re-sensitize tumors to PD-1 blockade, offering a novel biological strategy to overcome a major limitation of current immuno-oncology treatments.
Regulatory Significance
From a regulatory standpoint, IMMUNOLIFE is a GCP-governed Phase 2 randomized study enrolling 162 patients across 14 clinical centers in France. Patients are randomized 1:1 to receive MaaT033 plus cemiplimab or best investigator’s choice (BIC), with the primary endpoint focused on disease control rate at 12 weeks. MaaT033 has already received Orphan Drug Designation from the European Medicines Agency (EMA), underscoring regulatory recognition of its potential to address unmet medical need. An interim futility analysis planned for H1 2027 further reflects regulatory best practices in adaptive clinical development.
Business Significance
Advertisement
Strategically, the initiation of patient randomization represents a key clinical execution milestone for MaaT Pharma as it expands beyond hemato-oncology into solid tumor indications. IMMUNOLIFE complements the company’s broader exploratory strategy, which includes the PICASSO Phase 2a trial evaluating another microbiome therapy in metastatic melanoma. Together, these studies will inform pipeline prioritization, indication selection, and future investment decisions, while also generating high-value clinical data to support next-generation candidates such as MaaT034, a synthetic, donor-independent microbiome therapy optimized for large-scale oncology indications.
Patients’ Significance
For patients with advanced NSCLC, the study addresses a critical therapeutic gap. Many individuals who initially benefit from ICIs ultimately experience disease progression, particularly after antibiotic exposure that disrupts gut microbiota. IMMUNOLIFE offers the potential for a non-cytotoxic, adjunctive approach aimed at restoring responsiveness to immunotherapy rather than replacing it. If successful, this strategy could extend disease control and improve survival prospects in a population with limited treatment options, while minimizing additional treatment-related toxicity.
Policy Significance
At a policy level, the trial highlights the increasing role of microbiome science in regulated oncology drug development. Public funding support from the French National Research Agency for the IMMUNOLIFE consortium reflects national and European priorities to advance precision medicine, translational research, and public-private collaboration. As regulators and policymakers seek to optimize immunotherapy outcomes, studies like IMMUNOLIFE contribute critical evidence on how host biology and treatment history influence therapeutic efficacy, potentially shaping future clinical guidelines.
Overall, the randomization of the first patient in the IMMUNOLIFE Phase 2 trial marks an important step forward for MaaT Pharma and the broader field of microbiome-based immuno-oncology. By rigorously evaluating MaaT033 in a well-defined, ICI-resistant NSCLC population, the study aims to generate clinically actionable insights into overcoming immunotherapy resistance. For the cGxP community, IMMUNOLIFE exemplifies how innovative biology, disciplined clinical design, and regulatory alignment can converge to address some of the most pressing challenges in modern cancer care.
Source: MaaT Pharma press release
